transparency
UK government cautious on trial transparency
June 4, 2013Research and Development, Sales and Marketing Goldacre, UK, alltrials, transparency
Two ministers with responsibility for life sciences in the UK struck a cautious note over clinical trial transparency at an …
Europe votes yes on greater trial transparency
June 3, 2013Research and Development, Sales and Marketing Europe, Goldacre, alltrials, transparency
Europe has taken one step closer to increasing clinical trial transparency on the continent after MEPs voted yes on new …
Grant NICE greater trial data access – report
May 29, 2013Research and Development, Sales and Marketing Goldacre, NICE, transparency, trials
A new report by the National Audit Office says NICE should be given greater powers to access clinical trial data. …
Court rules against EMA disclosure
May 2, 2013Medical Communications, Research and Development, Sales and Marketing AbbVie, EMA, Roche, transparency
The European Medicines Agency (EMA) has been ordered in an interim ruling by the General Court of the European Union …
‘No consensus’ on transparency
April 22, 2013Medical Communications, Research and Development, Sales and Marketing ABPI, Goldacre, Whitehead, all trials, transparency
An ABPI meeting on increasing the transparency of the way clinical trials are reported has thrown up more questions than …
AbbVie guards Humira data
March 13, 2013Sales and Marketing AbbVie, Abbott, Humira, RA, transparency
AbbVie has issued two injunctions against the European Medicines Agency to prevent the regulator revealing data about rheumatoid arthritis drug …
John LaMattina: Pharma’s reputation continues to suffer – what can be done to fix it?
February 21, 2013Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bad pharma, Goldacre, John LaMattina, industry, transparency
You don’t have too look far to find unflattering articles about the pharmaceutical industry. What was previously the domain of …
NHS patient data and clinical research – coming together at last?
January 28, 2013Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Les Rose, NHS, R&D, clinical, records, transparency
In the mid-1990s, an NHS teaching hospital close to my offices invited proposals for expanding its clinical trials unit. Hitherto …
EMA’s five points on data release
November 27, 2012Medical Communications, Research and Development, Sales and Marketing EFPIA, EMA, Rasi, transparency
The European Medicines Agency has highlighted five areas that need to be ironed out before it begins publishing clinical trial …
EFPIA rejects ‘indiscriminate’ transparency
November 16, 2012Medical Communications, Research and Development, Sales and Marketing EFPIA, Goldacre, transparency, trials
Europe’s pharma trade body has poured tepid water on the idea of open access to clinical trial data, saying that …
EMA backs full access to trial data
April 12, 2012Business Services, Research and Development, Sales and Marketing EMA, clinical trial data, data disclosure, regulatory affairs, transparency
The European Medicines Agency says it wants to open up access to full clinical trial data, but warns that some …
FDA goes public with enforcement actions
June 2, 2011Manufacturing and Production FDA, transparency
The FDA is to publish more details about inspections and court actions on its website as part of a drive …
FDA launches online transparency initiative
January 11, 2011Medical Communications, Research and Development, Sales and Marketing FDA, Joshua Sharfstein, transparency
The FDA has launched a new online resource to increase the transparency of its processes and help save companies time …
EMA to widen public access to documents
December 1, 2010Research and Development, Sales and Marketing EMA, European Medicines Agency, European Ombudsman, patient information, transparency
The European Medicines Agency has agreed to give greater access to documents on medicines for human and veterinary use, after …
European pharma expects regulatory compliance challenges
November 18, 2010Sales and Marketing CRM, Cegedim Dendrite, Transparency Directive, regulatory compliance, transparency
European pharma companies will face major challenges over the next three years implementing new regulatory legislation and compliance requirements, according …
Latest content
Global coalition calls for stronger government action on COPD
Global health researchers call for more equitable partnerships
Liverpool launches £20m lab for infectious disease drug discovery
Circle Health Group expands into UK laboratory operations
FibroFind appoints Professor Andrew Fisher as Chief Medical Officer
